2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Rhabdomyosarcoma
5
Prostatic Neoplasms
5
Sarcoma, Synovial
3
Osteosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Liposarcoma
2
Leiomyosarcoma
2
Hemangiosarcoma
2
Head and Neck Neoplasms
2
Fibrosarcoma
2
Colorectal Neoplasms
2
Adrenocortical Carcinoma
2
Zollinger-Ellison Syndrome
1
Wilms Tumor
1
Uveal Melanoma
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Pinealoma
1
Interventions
Fluorouracil
219
Leucovorin
202
Oxaliplatin
192
Irinotecan
150
Bevacizumab
110
Capecitabine
94
Cetuximab
90
Folfox protocol
54
Chemotherapy, Adjuvant
36
Panitumumab
30
Colonoscopy
30
pembrolizumab
23
Drug Therapy
23
Nivolumab
22
Magnetic Resonance Spectroscopy
22
Gemcitabine
21
Blood Specimen Collection
20
Radiotherapy
19
Floxuridine
19
Biopsy
19
Neoadjuvant Therapy
18
Laparoscopy
18
IFL protocol
18
Early Intervention, Educational
18
Celecoxib
18
Surveys and Questionnaires
17
Surgical Procedures, Operative
16
Immunohistochemistry
16
Exercise
16
trifluridine tipiracil drug combination
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts